Dr. Jacobs is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1021 Morehead Medical Dr
Ste A
Charlotte, NC 28204Phone+1 980-442-2000Fax+1 704-355-5800- Is this information wrong?
Summary
- Clinical Director, Division of Lymphoma Therapy & Research; Dept of Hematologic Oncology, BMT & Blood Disorders; Levine Cancer Institute/Atrium Health, Charlotte, NC
Dr. Jacobs joined the Levine Cancer Institute (LCI) in Charlotte, NC in 2015 where he has served as a CLL and lymphoma specialist since that time. He functions as a principle investigator on numerous clinical trials and now serves as the clinical director of the lymphoma division. Dr. Jacobs has both a clinical and research focus in patients with Chronic Lymphocytic Leukemia (CLL). In his role as a principal investigator, he oversees the clinical trials conducted at Levine Cancer Institute that involve the treatment of patients with CLL and lymphoma. Dr. Jacobs graduated from Baylor College of Medicine in Houston, TX in 2009. He then completed his internship and residency in internal medicine at Vanderbilt University in Nashville, TN in 2012. Dr. Jacobs returned to Houston and completed his training with his hematology/oncology fellowship at MD Anderson Cancer Center in 2015.
He has more than 20 publications and over 500 citings.
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2012 - 2015
Vanderbilt University Medical CenterResidency, Internal Medicine, 2009 - 2012
Baylor College of MedicineClass of 2009
Certifications & Licensure
NC State Medical License 2015 - 2024
TX State Medical License 2012 - 2017
TN State Medical License 2011 - 2012
Clinical Trials
Publications & Presentations
PubMed
- Genetic Predictors of Ibrutinib-related Cardiovascular Side Effects in Patients with Chronic Lymphocytic Leukemia.Issam S Hamadeh, Jai N Patel, Ryan Jacobs, Hang Zeng, Jiaxian He, Bei Hu, Tamara Kay Moyo, Amy Soni, Steven Park, Ed Copelan, Belinda Avalos, Alicia Hamilton, Nury Ste...> ;Clinical Cancer Research. 2023 Dec 1
- 5 citationsOutcomes in Patients with High-Risk Features after Fixed-Duration Ibrutinib plus Venetoclax: Phase II CAPTIVATE Study in First-Line Chronic Lymphocytic Leukemia.Barr, P. M., Barr, P. M., John N Allan, Ian W Flinn, Tanya Siddiqi, Paolo Ghia, Constantine S Tam, Thomas J Kipps, Paul M Barr, Anna Elinder Camburn, Alessandra Tedesc...> ;Clinical Cancer Research. 2023 Jul 14
- Real-World Comparison of First-Line Treatment Adherence Between Single-Agent Ibrutinib and Acalabrutinib in Patients with Chronic Lymphocytic Leukemia.Xiaoxiao Lu, Bruno Emond, Laura Morrison, Frederic Kinkead, Patrick Lefebvre, Marie-Hélène Lafeuille, Wasiulla Khan, Linda H Wu, Zaina P Qureshi, Ryan Jacobs> ;Patient Preference and Adherence. 2023 Jan 1
- Join now to see all
Press Mentions
Long Term Follow-up of Ibrutinib + Venetoclax as First-Line Treatment for Chronic Lymphocytic Leukemia (CLL) (CAPTIVATE Study)December 21st, 2022
Hospital Affiliations
Atrium Health's Carolinas Medical CenterCharlotte, North Carolina
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
